🏆 Deal of the Week · CW 40/2021
Neumora raised USD 500 million in a Series A round; the post-money valuation was not disclosed. The round was backed by a syndicate co-anchored by ARCH Venture Partners and SoftBank, alongside six additional institutional investors. The financing was recognised as Venionaire DealMatrix Deal of the Week for KW 40/2021.
Neumora — key deal facts
| Company | Neumora |
| Founded | 2019 |
| Headquarters | Watertown, MA, United States |
| Amount raised | USD 500M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series A |
| Investors | ARCH Venture Partners (https://www.archventure.com/) SoftBank (https://group.softbank/en) Waycross Ventures (https://www.crunchbase.com/organization/waycross-ventures) Surveyor Capital (https://www.citadel.com/investment-strategies/surveyor-capital/) re.Mind Capital Polaris Partners Newpath Management Mubadala Capital |
| Sectors | BioTech |
Who invested in Neumora?
The round brought together ARCH Venture Partners, SoftBank, Waycross Ventures, Surveyor Capital, re.Mind Capital, Polaris Partners, Newpath Management, and Mubadala Capital. The investor mix is notable for spanning deep-science venture (ARCH Venture Partners, Polaris Partners), global technology growth capital (SoftBank), a multi-strategy hedge fund sleeve (Surveyor Capital via Citadel), and sovereign wealth exposure (Mubadala Capital), reflecting broad conviction across institutional categories for a single Series A in the neuroscience space.
What does Neumora do?
Neumora Therapeutics is a clinical-stage biotechnology company headquartered in Watertown, Massachusetts, founded in 2019. The company operates a data-driven precision neuroscience platform to identify and drug validated targets across neuropsychiatric and neurodegenerative disorders. Its lead asset, navacaprant, is an oral kappa opioid receptor antagonist currently in Phase 3 clinical trials for major depressive disorder. A second programme, NMRA-511, is in early-stage evaluation for agitation associated with Alzheimer's disease. The company was co-founded by Paul L. Berns, who serves as chairman and chief executive officer, together with scientists including Morgan Sheng of the Broad Institute and the founding team at ARCH Venture Partners.
Neumora valuation & multiples
Explore the benchmarks: Series A.
Frequently asked questions
How much did Neumora raise in its Series A?
Neumora raised USD 500 million in its Series A round, announced in KW 40/2021.
What is Neumora's valuation?
Neumora's post-money valuation following its Series A has not been publicly disclosed.
Who invested in Neumora?
The Series A was backed by ARCH Venture Partners, SoftBank, Waycross Ventures, Surveyor Capital, re.Mind Capital, Polaris Partners, Newpath Management, and Mubadala Capital.
When was Neumora founded and where is it based?
Neumora was founded in 2019 and is headquartered in Watertown, Massachusetts, United States.
Source: original announcement — read the full report.